Mar 14 2011
On March 11, 2011, the United States District Court for the District of Delaware issued a decision as to a portion of the patent litigation brought by Cephalon Inc. (Nasdaq: CEPH), ("Cephalon") and its wholly-owned subsidiary CIMA Labs, Inc., ("CIMA") against Watson Pharmaceuticals, Inc., and its wholly-owned subsidiary Watson Laboratories, Inc., (collectively "Watson") pertaining to Cephalon's FENTORA® fentanyl buccal tablet product. The Court ruled in Watson's favor on two of the three patents at issue in the case. The Court has yet to rule on the third patent.
"This decision does not resolve the litigation," said Jerry Pappert, Cephalon's Executive Vice President and General Counsel. "We remain confident in the strength of our claims with respect to the third patent. In the interim, we are reviewing the court's opinion with respect to the first two patents and are evaluating our options, including an appeal."
SOURCE Cephalon, Inc.